Log In
Print
BCIQ
Print
Print this Print this
 

Niox Vero

  Manage Alerts
Collapse Summary General Information
Company Circassia Pharmaceuticals plc
DescriptionBattery-powered, handheld point-of-care device to measure fractional exhaled nitric oxide (FeNO) as an assessment of airway inflammation
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentMarketed
Standard IndicationInflammation, Diagnostic
Indication DetailsMeasure airway inflammation to diagnose asthma
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$215.1M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today